RenovoRx, Inc.
RNXT- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001574094
No open-market purchases or sales by RenovoRx, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $9.00M in total; no superinvestor holds it.
13F holders, Q4 2022
Institutional positions in RenovoRx, Inc. as of Dec 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −2 vs. Q3 2022
- Shares held
- 1.17M
- −61.1K (−5.0%) vs. Q3 2022
- Total value
- $2.75M
- +$261.1K (+10.5%) vs. Q3 2022
- New holders
- 0
- 4 more added
- Sold out
- 2
- 3 more reduced
Compare with Q3 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RNXT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 28 | $9.00M |
| Q1 2026 | 31 | $8.58M |
| Q4 2025 | 33 | $6.83M |
| Q3 2025 | 31 | $9.04M |
| Q2 2025 | 25 | $11.6M |
| Q1 2025 | 27 | $9.98M |
| Q4 2024 | 18 | $1.31M |
| Q3 2024 | 13 | $2.00M |
| Q2 2024 | 17 | $1.01M |
| Q1 2024 | 10 | $441.6K |
| Q4 2023 | 12 | $758.1K |
| Q3 2023 | 14 | $473.5K |
| Q2 2023 | 9 | $552.2K |
| Q1 2023 | 12 | $9.64M |
| Q4 2022 | 11 | $2.75M |
| Q3 2022 | 13 | $2.49M |
| Q2 2022 | 11 | $2.35M |
| Q1 2022 | 12 | $482.0K |
| Q4 2021 | 9 | $506.0K |
| Q3 2021 | 8 | $1.02M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2022
Shares, value and share of portfolio for each institution holding RenovoRx, Inc.; share changes are against Q3 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 14 | $32 | 0.00% | −33,612−100.0% | Reduced |
| Wells Fargo & Company | 41 | $96 | 0.00% | +1+2.5% | Added |
| Morgan Stanley | 328 | $771 | 0.00% | −100−23.4% | Reduced |
| Tower Research Capital LLC (TRC) | 4,116 | $10.0K | 0.00% | −378−8.4% | Reduced |
| Vanguard Group Inc | 10,941 | $25.7K | 0.00% | +126+1.2% | Added |
| Cambridge Investment Research Advisors, Inc. | 14,400 | $34.0K | 0.00% | 00.0% | Unchanged |
| Affinity Capital Advisors, LLC | 15,259 | $35.9K | 0.01% | +4,009+35.6% | Added |
| Colony Group LLC | 15,741 | $37.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 36,107 | $84.0K | 0.00% | +1,805+5.3% | Added |
| Cohen Lawrence B | 97,165 | $228.3K | 0.12% | 00.0% | Unchanged |
| Bank of the West | 975,000 | $2.29M | 0.27% | 00.0% | Unchanged |
| Stifel Financial Corp | 0 | $0 | 0.00% | −31,678−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −1,256−100.0% | Sold out |